


	<p><b>Luisa lamele</b> <b>Curriculum Vitae</b></p> 
<p><b>WORK EXPERIENCE</b></p> <p>2018- 2017- 2012 - 2018 2013- 2002-2011</p>	<p>Tecnico laureato, Dept. of Molecular Medicine, University of Pavia, Italy Professore a contratto, Dept. of Biology and Biotechnology, University of Pavia, Italy Assegnista di Ricerca, Dept. of Molecular Medicine, University of Pavia, Italy Co-founder and Shareholder of ARDIS S.r.l. (University of Pavia Spin-off) Research Associate, University of Cambridge, UK</p>
<p><b>ACADEMIC EDUCATION</b></p> <p>1997-2000 1998 1991-1997</p>	<p>PhD in Fisiopatologia Sperimentale, University of Pavia, Italy Training for State Examination as Biologist Degree in Biology, 110/110 cum laude, University of Pavia, Italy</p>
<p><b>SCIENTIFIC BACKGROUND</b></p>	<p>I worked as undergraduate student and later on as PhD student at the Institute of General Pathology of the University of Pavia. During my traineeship and PhD I studied mutations of mitochondrial DNA and consequent alterations of tissues like liver and muscle induced by oxidative chemicals.</p> <p>In 1999 I moved to the laboratory of prof. E Gherardi, at the Oncology department of Cambridge University (UK), where I initially worked on the cloning and expression of soluble fragments of the tyrosine kinase receptor MET. Subsequently my interest has turned towards translational research with the aim of generating monoclonal antibodies against the MET receptor for cancer therapy. This project gave me the opportunity to collaborate with top research scientists in the field of the MET receptor, like G. Vande Woude at the Van Andel Institute in Michigan (US) and T. Johns at the Ludwig Institute, in Melbourne Australia. Moreover, I collaborated with companies specialised in generation of monoclonal antibodies, like Bioventix Ltd and UCB CellTech, where I spent eight months working on a joint project of monoclonal antibodies production towards the MET receptor.</p> <p>At the Department of Molecular Medicine of the University of Pavia, where I moved since 2012, I continued my post-doctoral work focusing on monoclonal antibodies to the MET receptor and other cancer targets with multiple aims: i) on a basic research level, with the purpose of using antibody fragments as “chaperones” molecules to facilitate crystallisation of the MET receptor for structural studies; ii) at the translational level, the project has therapeutic purposes in the field of regenerative medicine and iii) for generation of diagnostic tools.</p> <p>In the context of the University Spin-off of which I am co-founder I also work on the generation of monoclonal antibodies against some other specific receptors involved in specific tumours with the aim of developing therapeutic molecules.</p> <p>Since 2018 I have been appointed as specialised technical staff at the Department of Molecular Medicine, University of Pavia, for support to teaching and research.</p>
<p><b>LIST OF PUBLICATIONS</b> <b>BOOK CHAPTERS</b></p>	<ol style="list-style-type: none"> <li>1. Translation from English to Italian of chapter 12 “<i>Antigen Processing and Presentation</i>” and appendix B “<i>Antigen Names with CD Designation Equivalents</i>” from the book “<i>Immunology, infection and immunity</i>” by Pier, Lyczak, Wetzler. Italian publisher, PICCIN Spa, Padova (Italy), title “<i>Immunologia, infezione, immunita</i>”, 2005</li> <li>2. Ermanno Gherardi, <b>Luisa lamele</b>, Hugo de Jonge <i>Growth factors and tumour progression</i>. Le nicchie delle cellule staminali somatiche normali e tumorali, 2013 Cap.9: 42-47</li> <li>3. E Gherardi, H de Jonge, C Scotti, <b>L lamele</b> <i>Ingegnerizzazione di mAb per scopi terapeutici</i> Chapter 9 of the textbook “<i>Farmacologia Generale e Molecolare</i>”, 5ed. Edizioni EDRA, 2018</li> </ol>

JOURNAL PAPERS	<ol style="list-style-type: none"> <li>1. Giovanni de Nola, Bérénice Leclercq, Alexandra Mougel, Solenne Taront, Claire Simonneau, Federico Forneris, Eric Adriaenssens, Hervé Drobecq, <b>Luisa lamele</b>, Laurent Dubuquoy, Oleg Melnyk, Ermanno Gherardi, Hugo de Jonge, and Jérôme Vicogne. 2022. <i>Dimerization of krigle 1 domain from hepatocyte growth factor/scatter factor provides a potent MET receptor agonist</i>. Life Sci Alliance 5, 12 (2022), e202201424. <a href="https://doi.org/10.26508/lsa.202201424">https://doi.org/10.26508/lsa.202201424</a></li> <li>2. [Victor M. Baart, Geertje van der Horst, Marion M. Deken, Shadhvi S. Bhairosingh, Timo Schomann, Vincent Q. Sier, Maaïke H. van der Mark, <b>Luisa lamele</b>, Hugo de Jonge, Massimo Resnati, Andrew P. Mazar, Rob C.M. Pelger, Gabriel van der Pluijm, Peter J.K. Kuppen, Alexander L. Vahrmeijer, and Cornelis F.M. Sier. 2021. <i>A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma</i>. Eur J Cancer 146, (2021), 11–20. <a href="https://doi.org/10.1016/j.ejca.2021.01.001">https://doi.org/10.1016/j.ejca.2021.01.001</a></li> <li>3. Vallarola A, Tortarolo M, De Gioia R, <b>lamele L</b>, de Jonge H, de Nola G, Bovio E, Pasetto L, Bonetto V, Freschi M, Bendotti C, Gherardi E. <i>A Novel HGF/SF Receptor (MET) Agonist Transiently Delays the Disease Progression in an Amyotrophic Lateral Sclerosis Mouse Model by Promoting Neuronal Survival and Dampening the Immune Dysregulation</i>. Int J Mol Sci. 2020 Nov 12;21(22):8542</li> <li>4. Lüdel F, Bufe S, Bley Müller WM, de Jonge H, <b>lamele L</b>, Niemann HH, Hellweg T. <i>Distinguishing Between Monomeric scFv and Diabody in Solution Using Light and Small Angle X-ray Scattering</i>. Antibodies (Basel). 2019 Sep 23;8(4):48</li> <li>5. Andres F, <b>lamele L</b>, Meyer T, Stüber JC, Kast F, Gherardi E, Niemann HH, Plückthun A. <i>Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking</i>. J Mol Biol. 2019 May 3;431(10):2020-2039</li> <li>6. Duranti C, Carraresi L, Sette A, Stefanini M, Lottini T, Crescioli S, Crociani O, <b>lamele L</b>, De Jonge H, Gherardi E, Arcangeli A. <i>Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging</i>. Oncotarget. 2018 Oct 9;9(79):34972-34989</li> <li>7. Cichero E, Fresia C, Guida L, Booz V, Millo E, Scotti C, <b>lamele L</b>, de Jonge H, Galante D, De Flora A, Sturla L, Vigliarolo T, Zocchi E, Fossa P. <i>Identification of a high affinity binding site for abscisic acid on human lanthionine synthetase component C-like protein 2</i>. The International Journal of Biochemistry &amp; Cell Biology 97, 52–61 (2018).</li> <li>8. <b>Luisa lamele</b>, Luca Vecchia, Claudia Scotti <i>Antibody–drug conjugates: targeted weapons against cancer</i>. Antibody Technology Journal, 2015 Jan (5):1-13</li> <li>9. Sameer A Greenall, Ermanno Gherardi, Zhanqi Liu, Jacqueline F Donoghue, Angela A Vitali, Qian Li, Roger Murphy, <b>Luisa lamele</b>, Andrew M Scott, Terrance Johns <i>Non-Agonistic Bivalent Antibodies That Promote c-Met Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-Met</i>. PLoS ONE, 2012 Apr 12; 7(4): 1-10</li> <li>10. Gherardi E, Youles ME, Miguel RN, Blundell TL, <b>lamele L</b>, Gough J, Bandyopadhyay A, Hatmann G, Butler PJ <i>Functional map domain structure of MET, the product of c-met proto-oncogene and receptor for hepatocyte growth factor/scatter factor</i>. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12039-44</li> <li>11. C Scotti, <b>L lamele</b>, A Alessandrini, V Vannini, O Cazzalini, MC Lazzè, R Melli, M Savio, R Pizzala LA. Stivala, S Biglieri, A Tomasi, L Bianchi <i>Lack of molecular relationships between lipid peroxidation and mitochondrial DNA single strand breaks in isolated rat hepatocytes and mitochondria</i>. Mitochondrion, 2 (2003) 361–373</li> <li>12. Cazzalini O, Lazzè MC, <b>lamele L</b>, Stivala LA, Bianchi L, Vaghi P, Cornaglia A, Calligaro A, Curti D, Alessandrini A, Prosperi E, Vannini V. <i>Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes</i>. Biochem Pharmacol. 2001 Oct 1;62(7):893-902</li> </ol>
----------------	--